These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36502651)

  • 21. Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
    van Leyen K; Roelcke U; Gruber P; Remonda L; Berberat J
    J Neuroimaging; 2019 Sep; 29(5):645-649. PubMed ID: 31112344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
    Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
    J Neurooncol; 2011 Jun; 103(2):353-60. PubMed ID: 20848300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma.
    Iv M; Naya L; Sanan S; Van Buskirk SL; Nagpal S; Thomas RP; Recht LD; Patel CB
    Neuroradiol J; 2024 Feb; 37(1):107-118. PubMed ID: 37931176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
    Tran AN; Lai A; Li S; Pope WB; Teixeira S; Harris RJ; Woodworth DC; Nghiemphu PL; Cloughesy TF; Ellingson BM
    Neuro Oncol; 2014 Mar; 16(3):414-20. PubMed ID: 24305712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.
    Lukács G; Tóth Z; Sipos D; Csima M; Hadjiev J; Bajzik G; Cselik Z; Semjén D; Repa I; Kovács Á
    Ideggyogy Sz; 2018 Mar; 71(3-04):95-103. PubMed ID: 29889468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
    Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
    Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatial heterogeneity of edema region uncovers survival-relevant habitat of Glioblastoma.
    Yang Y; Han Y; Zhao S; Xiao G; Guo L; Zhang X; Cui G
    Eur J Radiol; 2022 Sep; 154():110423. PubMed ID: 35777079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
    Chaddad A; Sabri S; Niazi T; Abdulkarim B
    Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma.
    Cui Y; Ren S; Tha KK; Wu J; Shirato H; Li R
    Eur Radiol; 2017 Sep; 27(9):3583-3592. PubMed ID: 28168370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differentiation between progression and pseudoprogresion by arterial spin labeling MRI in patients with glioblastoma multiforme.
    Jovanovic M; Radenkovic S; Stosic-Opincal T; Lavrnic S; Gavrilovic S; Lazovic-Popovic B; Soldatovic I; Maksimovic R
    J BUON; 2017; 22(4):1061-1067. PubMed ID: 28952228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time trends in glioblastoma multiforme survival: the role of temozolomide.
    Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT
    Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [F-DOPA PET/MR based target definiton in the 3D based radiotherapy treatment of glioblastoma multiforme patients. First Hungarian experiences].
    Sipos D; Tóth Z; Lukács G; Bajzik G; Hadjiev J; Cselik Z; Repa I; Kovács Á
    Ideggyogy Sz; 2019 May; 72(5-6):209-215. PubMed ID: 31241266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
    Gainer JL; Sheehan JP; Larner JM; Jones DR
    J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
    Barajas RF; Chang JS; Segal MR; Parsa AT; McDermott MW; Berger MS; Cha S
    Radiology; 2009 Nov; 253(2):486-96. PubMed ID: 19789240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glioblastoma multiforme versus solitary supratentorial brain metastasis: differentiation based on morphology and magnetic resonance signal characteristics.
    Maurer MH; Synowitz M; Badakshi H; Lohkamp LN; Wüstefeld J; Schäfer ML; Wiener E
    Rofo; 2013 Mar; 185(3):235-40. PubMed ID: 23196836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
    Cho HR; Kumari N; Thakur N; Vu HT; Kim H; Choi SH
    Sci Rep; 2019 Nov; 9(1):16613. PubMed ID: 31719653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiomic analysis of multi-contrast brain MRI for the prediction of survival in patients with glioblastoma multiforme.
    Chaddad A; Desrosiers C; Toews M
    Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():4035-4038. PubMed ID: 28325002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.